Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2022 on file Net Income-$3.32M-$3.32MderivedN/M vs Q4 2022 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Operating Incomederived-$4,988,000N/M Operating Cash Flowderived-$3,592,000N/M Free Cash Flowderived-$3,592,000N/M ended Dec 31, 2023 · filed Apr 2, 2024 · 93 d after period end